In 2005, a prospective, randomized, phase 3 trial by the European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) reported improved progression-free and overall survival for patients with Glioblastoma with the addition of concomitant and adjuvant temozolomide (TMZ), an oral alkylating agent, to radiotherapy (RT) following maximal safe resection 1).